Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer
Candel Therapeutics, Inc.
Candel Therapeutics Inc. (CADL)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Portolan Capital Management George Mccabe | 1,384,142 | $7,059,124 | -15% | 0.38% |
| 2. | Citadel Investment Group Ken Griffin | 252,291 | $1,286,684 | 0% | |
| 3. | Millennium Management Israel Englander | 136,670 | $697,017 | 0% | |
| 4. | 123,900 | $631,890 | -60% | 0% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 103,847 | $529,621 | -36% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.00 | 750,000 | $4,500,000.00 | 1,303,752 | 2024-12-16 | Filing | |
| $6.00 | 500,000 | $3,000,000.00 | 1,142,406 | 2024-12-16 | Filing | |
| $1.92 | 23,950 | $45,984.00 | 152,000 | 2022-12-09 | Filing | |
| $1.68 | 3,050 | $5,124.00 | 128,050 | 2022-12-08 | Filing | |
| $1.61 | 1,238 | $1,993.18 | 2,738 | 2022-12-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.98 | 937 | $6,540.26 | 52,493 | 2025-07-28 | Filing | |
| $5.04 | 781 | $3,936.24 | 52,493 | 2025-06-30 | Filing | |
| $8.76 | 45,316 | $396,995.35 | 52,493 | 2025-03-18 | Filing | |
| $8.76 | 32,146 | $281,672.90 | 96,527 | 2025-03-18 | Filing | |
| $9.00 | 400 | $3,601.00 | 225,740 | 2025-03-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,233,385 | $41,990,263 | 0% | |
| 2. | 2,580,517 | $13,160,637 | 6.68% | |
| 3. | 2,379,330 | $12,134,582 | 0% | |
| 4. | 2,007,112 | $10,236,272 | 0% | |
| 5. | 928,197 | $4,734,652 | 0% |
News See All
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025
Candel Therapeutics, Inc.
Hedge Fund and Insider Trading News: Ray Dalio, Michael Novogratz, Bitwise Asset Management, Goldman Sachs Group Inc. (GS), Candel Therapeutics Inc (CADL), Cintas Corporation (CTAS), and More
The asset-management arm of Michael Novogratz’s Galaxy Digital is aiming to hire its first chief operating officer as the division scales and increasingly moves into running actively managed crypto ...